obesity drug news today glp-1 2025 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio GLP-1s and Obesity Coverage: Differing

10.1016/j.jclinane.2023.111091 [DOI] [PubMed] 23.Santos LB, Mizubuti GB, da Silva LM, Silveira SQ, Nersessian RSF, Abib ACV et al (2024) Effect of various perioperative semaglutide interruption intervals on residual gastric content assessed by esophagogastroduodenoscopy: a retrospective single center observational study

Atrium can help patients prepare by documenting BMI, weight-related conditions, prior treatment history, medication tolerance, labs, and the clinical reason a GLP-1 is being considered

Tau is a core component in the AD pathology

High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels

While 12% of adults in the US have used GLP-1s, only 1% of eligible patients have received bariatric surgery

Staying informed through resources like SeekPeptides ensures you have access to the latest evidence as the field evolves